Opthea (ASX:OPT) Long-Term Debt : A$248.23 Mil (As of Dec. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Opthea Long-Term Debt?

Opthea's Long-Term Debt for the quarter that ended in Dec. 2024 was A$248.23 Mil.

Opthea's quarterly Long-Term Debt increased from Dec. 2023 (A$0.00 Mil) to Jun. 2024 (A$213.18 Mil) and increased from Jun. 2024 (A$213.18 Mil) to Dec. 2024 (A$248.23 Mil).

Opthea's annual Long-Term Debt increased from Jun. 2022 (A$0.00 Mil) to Jun. 2023 (A$127.63 Mil) and increased from Jun. 2023 (A$127.63 Mil) to Jun. 2024 (A$213.18 Mil).

Opthea Long-Term Debt Historical Data

The historical data trend for Opthea's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Long-Term Debt Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Long-Term Debt

Get a 7-Day Free Trial

127.63

213.18

Opthea Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															-	127.63	-	213.18	248.23

Opthea (ASX:OPT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Opthea Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Opthea's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.